Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JS1K | ISIN: IE00B4Q5ZN47 | Ticker-Symbol: J7Z
Tradegate
05.06.25 | 18:03
95,92 Euro
+0,84 % +0,80
1-Jahres-Chart
JAZZ PHARMACEUTICALS PLC Chart 1 Jahr
5-Tage-Chart
JAZZ PHARMACEUTICALS PLC 5-Tage-Chart
RealtimeGeldBriefZeit
96,8497,1217:18
96,8497,1217:18

Aktuelle News zur JAZZ PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoNeedham Says Promising Data Underscore Growth Potential for Jazz Pharma (JAZZ)1
DiJazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer Study2
DiUBS maintains buy rating on Jazz Pharmaceuticals stock after positive trial data1
DiUBS behält Kaufempfehlung für Jazz Pharmaceuticals nach positiven Studiendaten bei4
DiThe Analyst Verdict: Jazz Pharmaceuticals In The Eyes Of 11 Experts3
JAZZ PHARMACEUTICALS Aktie jetzt für 0€ handeln
DiRoche/Jazz Pharmaceuticals share positive phase 3 results for lung cancer combination therapy6
MoJazz Pharmaceuticals succeeds in late-stage study of lung cancer treatment2
MoJazz Pharmaceuticals reports promising Phase 2 trial results for Ziihera2
MoJazz Pharmaceuticals berichtet über vielversprechende Ergebnisse der Phase-2-Studie für Ziihera2
MoJazz Pharmaceuticals plc: Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ...37Phase 2 trial results continue to show clinically meaningful efficacy and durable responses, including 36.5-month median overall survival after four years of follow-up...
► Artikel lesen
21.05.Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences229DUBLIN, May 21, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences: Jefferies...
► Artikel lesen
14.05.Major Purchase Alert: Seamus Mulligan Invests $9.99M In Jazz Pharmaceuticals Stock2
07.05.Jazz Pharmaceuticals plc - 10-Q, Quarterly Report9
06.05.Jazz Pharmaceuticals plc - 8-K, Current Report3
06.05.Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance500- Total revenues of $898 million in 1Q25 -- Xywav® and Epidiolex® revenues grew 9% and 10% year-over-year, respectively, in 1Q25 -- Completed submission of sNDA for Zepzelca® in 1L ES-SCLC...
► Artikel lesen
06.05.Avadel Pharma gains after appeals court ruling in Lumryz case with Jazz Pharma5
05.05.Jazz Pharmaceuticals Q1 2025 Earnings Preview6
05.05.Preview: Jazz Pharmaceuticals' Earnings2
30.04.Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference290DUBLIN, April 30, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the BofA Securities 2025 Healthcare Conference. Company...
► Artikel lesen
25.04.PTC and Jazz Pharmaceuticals among latest firms to win EU backing for drugs2
Weiter >>
84 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2